溴隐亭治疗垂体瘤术后患者。
Bromocriptine treatment of postoperative prolactinoma patients.
作者信息
Yang D Y, Wang Y C
机构信息
Division of Neurosurgery, Taichung Veterans General Hospital, Taiwan, R.O.C.
出版信息
Zhonghua Yi Xue Za Zhi (Taipei). 1994 Jun;53(6):346-50.
BACKGROUND
Prolactinoma is the leading cause of pituitary adenoma. It causes amenorrhea in women and impotence in men. Surgical and bromocriptine treatment are the mainstays of therapy in most of the patients with this disease. Determining the outcome for postoperative hyperprolactinemia patients who received bromocriptine treatment was the main purpose of this study.
METHODS
Thirty-two patients who received operation for prolactinoma have been investigated. Twenty of them had received bromocriptine treatment before conception, 14 were diagnosed as having macroadenoma and all of them had post-operative hyperprolactinemia.
RESULTS
Five patients needed bromocriptine treatment of more than 12.5mg/day to decrease the serum prolactin level. Three patients received radiotherapy postoperatively. Other patients were bromocriptine sensitive. Eight of them had menses restored, and of these, five became pregnant.
CONCLUSIONS
Operation can successfully treat most of the patients with microadenoma. If there has postoperative hyperprolactinemia, bromocriptine treatment should be the first choice before radiotherapy.
背景
泌乳素瘤是垂体腺瘤的主要病因。它导致女性闭经和男性阳痿。手术和溴隐亭治疗是大多数该疾病患者的主要治疗方法。确定接受溴隐亭治疗的术后高泌乳素血症患者的预后是本研究的主要目的。
方法
对32例接受泌乳素瘤手术的患者进行了调查。其中20例在受孕前接受过溴隐亭治疗，14例被诊断为大腺瘤，且所有患者均有术后高泌乳素血症。
结果
5例患者需要每天服用超过12.5mg的溴隐亭来降低血清泌乳素水平。3例患者术后接受了放疗。其他患者对溴隐亭敏感。其中8例月经恢复，其中5例怀孕。
结论
手术可成功治疗大多数微腺瘤患者。如果术后出现高泌乳素血症，溴隐亭治疗应是放疗前的首选。
Zotero 插件